ALK and non-small cell lung carcinoma: The clinical model built by clinical characteristics failed to predict the prognosis as well, which demonstrated that the three clinical characteristics (sex, age, and smoking status) could not predict the prognosis in ALK-positive NSCLC treated with TKI crizotinib.